Point72 Asset Management
ALXN

Point72 Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Point72 Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$31.2M – 1295
2020
Q4 		$31.2M Sell
200,000
-1,166,848
-85% -$150M 0.15% 185
2020
Q3 		$156M Buy
1,366,848
+155,506
+13% +$16.8M 0.8% 13
2020
Q2 		$136M Buy
1,211,342
+568,997
+89% +$60.4M 0.89% 9
2020
Q1 		$57.7M Buy
642,345
+303,832
+90% +$29.8M 0.47% 45
2019
Q4 		$36.6M Sell
338,513
-80,728
-19% -$8.63M 0.19% 155
2019
Q3 		$41.1M Buy
419,241
+375,359
+855% +$42.3M 0.25% 121
2019
Q2 		$5.75M Buy
+43,882
New +$5.66M 0.03% 481
2019
Q1 		– Sell
-770,836
Closed -$75M – 1312
2018
Q4 		$75M Buy
770,836
+44,153
+6% +$5.22M 0.37% 73
2018
Q3 		$101M Buy
726,683
+288,883
+66% +$36.2M 0.42% 55
2018
Q2 		$54.4M Buy
437,800
+352,800
+415% +$41.2M 0.22% 131
2018
Q1 		$9.47M Sell
85,000
-137,737
-62% -$16.5M 0.04% 438
2017
Q4 		$26.6M Buy
222,737
+162,837
+272% +$19.8M 0.12% 247
2017
Q3 		$8.4M Sell
59,900
-362,700
-86% -$49.3M 0.04% 434
2017
Q2 		$51.4M Buy
422,600
+262,700
+164% +$30.6M 0.29% 90
2017
Q1 		$19.4M Sell
159,900
-238,300
-60% -$30.7M 0.11% 253
2016
Q4 		$48.7M Sell
398,200
-213,300
-35% -$26.1M 0.34% 76
2016
Q3 		$74.9M Buy
611,500
+82,000
+15% +$10.6M 0.53% 32
2016
Q2 		$61.8M Buy
529,500
+443,800
+518% +$63M 0.42% 46
2016
Q1 		$11.9M Buy
+85,700
New +$12.6M 0.09% 255
2014
Q3 		– Sell
-11,700
Closed -$1.83M – 807
2014
Q2 		$1.83M Buy
+11,700
New +$1.85M 0.01% 565

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's ALXN Position: Q1 2021 in Review

Point72 Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 200,000 shares — an estimated $31.2M sold.

Point72 Asset Management first reported a position in ALXN in Q2 2014 and held it in 20 quarters. The position peaked at $156M in Q3 2020. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Point72 Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Point72 Asset Management sold 200,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $31.2M.
  • Point72 Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 20 quarters.
  • Point72 Asset Management's Alexion Pharmaceuticals position peaked at $156M in Q3 2020.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Point72 Asset Management's 13F filing for Q1 2021, filed 17 May 2021.